
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
WIRB Copernicus Group® announced its acquirement of Vigilare International, a provider of integrated, end-to-end pharmacovigilance and drug safety solutions for the biopharmaceutical and biotech industry. This new acquistion is a perfect fit for both companies as Vigilare compliments WCG's existing clinical research solutions and they plan to identify more opportunities to streamline clinical research operations.
Read the full release






